June Sherie Almenoff
CIK: 0001492647
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (14 total)
- Sep 2, 2026ATNM
Actinium Pharmaceuticals, Inc.
Award(A)Direct18K shares- - Jan 9, 2026TENX
TENAX THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
30K shares- - Nov 18, 2025TENX
TENAX THERAPEUTICS, INC.
Purchase(P)Indirect1.9K shares at avg. $7.52$14K - Nov 18, 2025TENX
TENAX THERAPEUTICS, INC.
Purchase(P)Direct1.9K shares at avg. $7.52$14K - Nov 17, 2025TENX
TENAX THERAPEUTICS, INC.
Purchase(P)Indirect93 shares at avg. $7.15$664.95 - Nov 17, 2025TENX
TENAX THERAPEUTICS, INC.
Purchase(P)Direct93 shares at avg. $7.15$664.95 - Jul 1, 2025TENX
TENAX THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
80K shares- - Jun 17, 2025AVTX
Avalo Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.1K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
50K shares- - Mar 28, 2025AVTX
Avalo Therapeutics, Inc.
Exercise(M)Direct3.2K shares- - Dec 10, 2024TENX
TENAX THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
100K shares- - Nov 13, 2024AVTX
Avalo Therapeutics, Inc.
Purchase(P)Indirect500 shares at avg. $13.00$7K - Nov 12, 2024AVTX
Avalo Therapeutics, Inc.
Purchase(P)Indirect500 shares at avg. $12.50$6K - Nov 1, 2024ATNM
Actinium Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
50K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 2, 2026 |  ATNM Actinium Pharmaceuticals, Inc. | Award(A) | 18,000 | - | $0 | Direct |
| Jan 9, 2026 |  TENX TENAX THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
| Nov 18, 2025 | TENX TENAX THERAPEUTICS, INC. | Purchase(P) | 1,900 | $7.52 | $14,280 | Indirect |
| Nov 18, 2025 | TENX TENAX THERAPEUTICS, INC. | Purchase(P) | 1,900 | $7.52 | $14,280 | Direct |
| Nov 17, 2025 | TENX TENAX THERAPEUTICS, INC. | Purchase(P) | 93 | $7.15 | $665 | Indirect |
| Nov 17, 2025 | TENX TENAX THERAPEUTICS, INC. | Purchase(P) | 93 | $7.15 | $665 | Direct |
| Jul 1, 2025 | TENX TENAX THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 80,000 | - | - | Direct |
| Jun 17, 2025 |  AVTX Avalo Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,100 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 50,000 | - | - | Direct |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | Exercise(M) | 3,167 | - | - | Direct |
| Dec 10, 2024 | TENX TENAX THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 100,000 | - | - | Direct |
| Nov 13, 2024 | AVTX Avalo Therapeutics, Inc. | Purchase(P) | 500 | $13.00 | $6,500 | Indirect |
| Nov 12, 2024 | AVTX Avalo Therapeutics, Inc. | Purchase(P) | 500 | $12.50 | $6,250 | Indirect |
| Nov 1, 2024 | ATNM Actinium Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 50,000 | - | - | Direct |
1-14 of 14 transactions
About Almenoff June Sherie
Almenoff June Sherie (SEC CIK 0001492647) files insider reports with the SEC as Director of Actinium Pharmaceuticals, Inc. (ATNM), Director of TENAX THERAPEUTICS, INC. (TENX) and Director of Avalo Therapeutics, Inc. (AVTX).
Signal8 holds 12 ownership filings by Almenoff June Sherie (1 Form 3, 11 Form 4), filed between Nov 5, 2024 and Sep 4, 2026. Those filings report 14 transactions, from Nov 1, 2024 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Almenoff June Sherie's filings is in NEW YORK, NY.
Recent filings by Almenoff June Sherie
- Sep 2, 2026: Grant or award of ATNM shares (Form 4, code A).
- Jan 9, 2026: Grant or award of TENX derivative securities (Form 4, code A).
- Nov 18, 2025: Open-market purchases of TENX shares (2 lines, Form 4, code P).
- Nov 17, 2025: Open-market purchases of TENX shares (2 lines, Form 4, code P).
- Jul 1, 2025: Grant or award of TENX derivative securities (Form 4, code A).
Other insiders filing for Actinium Pharmaceuticals, Inc. (ATNM)
- David Matthew T, Chief Financial Officer
- Kamal Adeela, Chief Scientific Officer
- Heeger Steffen Wilhem, Chief Medical Officer
- Shetty Ajit, Director
- Nicholson, C. David, Director
- SETH SANDESH, Chief Executive Officer